Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company ...
Fierce Biotech

Voyager pauses Alzheimer's program just 8 months after unveiling asset

Voyager Therapeutics has hit pause on a preclinical Alzheimer’s disease program just eight months after unveiling the asset. The neurology biotech announced back in July 2025 that it was adding a new ...
Columbus Dispatch

MSTRO & DataCorps Launch Voyager Program with ‘Mission Control Network’ Initiative

SMBs have the same intelligence needs as enterprises. They need clarity, speed, and confidence in their data. The Voyager program and Mission Control Network allows us to deliver those capabilities.” ...
Morningstar

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s ...
Nasdaq

Voyager Provides Update on SOD1 ALS Gene Therapy Program

LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...